Medical/Pharmaceuticals

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

HANGZHOU, China and SAN FRANCISCO, July 12, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biopharmaceutical company focusing on discovering and developing innovative therapies to treat chronic, metabolic and immunological diseases, announced today the...

2021-07-12 08:00 3964

Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US

SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...

2021-07-11 21:03 20439

HICOOL 2021 Global Entrepreneurship Competition (Preliminary Round) is Launched in Full Swing on July 10th

BEIJING, July 11, 2021 /PRNewswire/ -- On July 10th, HICOOL 2021 Global Entrepreneurship Competition (Qualifying Round) is launched in full swing. A total of 1,237 startups shortlisted for the preliminary round compete off-line inBeijing and online in a global context in six major industries: New...

2021-07-11 21:00 2381

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 - Ortho is ...

2021-07-10 03:33 30376

Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer

STOCKHOLM, July 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onJuly 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac. The safety...

2021-07-09 21:38 3563

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile * ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Ko...

2021-07-09 21:00 3827

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...

2021-07-09 20:00 30564

Alzheimer's Disease Researchers Release Free Memory Tracking App

SAN DIEGO, July 9, 2021 /PRNewswire/ -- Today, Leucadia Therapeutics Inc, a California HealthTech Company, is launching 8 Apps that help exercise memory and cognition, including a personalized memory tracker called ProCogny (procogny.com). ProCogny allows users to play memory-intensive puzzles an...

2021-07-09 18:00 2512

Sequanta and Mission Bio announce strategic partnership

SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...

2021-07-09 15:44 2341

Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

SAN FRANCISCO, and SUZHOU, China, July 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-07-09 08:00 23926

Vaniam Group LLC announces European and International expansion with addition of new global agency, Vaniam Group Global Ltd

Dr. Louise Verrall appointed to lead Vaniam Group Global Ltd as Head of Europe & International CHICAGO, July 9, 2021 /PRNewswire/ -- Vaniam Group LLC today announced the establishment of Vaniam Group Global Ltd, expanding the company's strategic healthcare communications network footprint intoEu...

2021-07-09 06:50 2441

New Research Highlights Need for Health-Systems Approach to Vision Care

Study in The Gambia underscores success of local approach and policymaking. DALLAS, July 9, 2021 /PRNewswire/ -- A recent study of OneSight Vision Centers in TheGambia offers new insight into the importance of implementing a strengthening program for services that address poor vision through a he...

2021-07-09 03:14 2733

Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid Tumors Through the Precision Delivery of Alpha Radiation

JERUSALEM and WILMINGTON, Del., July 8, 2021 /PRNewswire/ -- Alpha Tau Medical Limited ("Alpha Tau"), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. ("HCC") (Nasdaq: HCCC), a special purpose acquisition company, today announced they have e...

2021-07-08 21:13 31574

Yushangmei seeks to establish partnership with a new target company

GUANGZHOU, China, July 8, 2021 /PRNewswire/ -- Guangzhou Yushangmei Health Management Co., Ltd. announced the termination of the partnership with the company headquartered inNevada, USA. Meanwhile, Yushangmei has sought to establish partnership with a new target company, specific details will be ...

2021-07-08 19:29 4702

COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them

New campaign, Let's treat it right, launches as online searches for self-care surge globally[1], as people take more responsibility for  their everyday health.  NYON, Switzerland, July 8, 2021 /PRNewswire/ -- Today sees the launch of Let's treat it right, a major new health education campaign d...

2021-07-08 16:00 2025

Nippon Express (India) Newly Acquires GDP Certification at Three Locations

TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...

2021-07-08 15:00 1680

COVID-19: Doctor's certificates for antigen self-tests now offered online worldwide by DrAnsay.com

HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.

2021-07-08 13:55 3813

BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer

SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...

2021-07-08 12:01 2673

Just 5 minutes: Game-changing PCR to complete nucleic acid amplification, Si-Gene Biotech help out against COVID 19

SHANGHAI, July 8, 2021 /PRNewswire/ -- As is known, nucleic acid detection is currently the "golden standard" of coronavirus detection and has the high sensitivity and specificity characteristics in early diagnosis. The most common method for detecting novel coronavirus-specific nucleic acid sequ...

2021-07-08 11:28 2533

BeatO raises USD 5.7 million in funding led by W Health Ventures

- Fresh funds to be utilized in enlarging its subscriber base across channels/geographies and for product enhancement to provide care for more cardiometabolic conditions NEW DELHI, July 8, 2021 /PRNewswire/ -- BeatO – India's leading digital care ecosystem for chronic condition management – has ...

2021-07-08 08:30 3779
1 ... 628629630631632633634 ... 650